What's in Akela Pharma, Inc.'s pipeline?

Akela Pharma, Inc. has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Akela Pharma, Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/akela-pharma-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Akela Pharma, Inc. — Portfolio Competitive Intelligence Brief

Akela Pharma, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Fentanyl TAIFUN	Fentanyl TAIFUN	phase 3	Opioid analgesic (synthetic opioid)	Mu-opioid receptor (OPRM1)	Pain Management

Therapeutic area mix

Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Akela Pharma, Inc.:

Cite this brief

Drug Landscape (2026). Akela Pharma, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/akela-pharma-inc. Accessed 2026-05-14.